CMKLR1 Antibody

What is CMKLR1 and what are its primary physiological functions?

CMKLR1 (also known as ChemR23, chemerin receptor, or chemokine-like receptor 1) functions as a receptor for both the adipokine chemerin/RARRES2 and the omega-3 fatty acid-derived molecule resolvin E1. It plays crucial roles in multiple biological processes through the activation of several intracellular signaling pathways including SKY, MAPK1/3 (ERK1/2), MAPK14/P38MAPK, and PI3K .

The receptor's activation results in diverse physiological outcomes:

• Reduction of immune responses

• Enhancement of adipogenesis and angiogenesis

• Regulation of adipocyte metabolism

• Participation in tau phosphorylation processes relevant to neurodegenerative diseases

• Acting as a coreceptor for several SIV strains (SIVMAC316, SIVMAC239, SIVMACL7E-FR, and SIVSM62A) and a primary HIV-1 strain (92UG024-2)

What detection methods are most effective for CMKLR1 in different tissue types?

Multiple methodological approaches can be employed for CMKLR1 detection, each with specific advantages depending on the experimental context:

• Western Blotting (WB): Effective for quantifying total CMKLR1 protein expression levels in tissue lysates and cell extracts. Several antibodies targeting different epitopes (AA 151-250, AA 250-350, etc.) are available with validated reactivity across human, mouse, and rat samples .

• Immunohistochemistry (IHC): Both paraffin-embedded and frozen section protocols have been optimized for CMKLR1 visualization in tissue architecture. For neural tissues where CMKLR1 has been implicated in Alzheimer's pathology, IHC provides critical spatial information about receptor distribution .

• Immunofluorescence (IF): Allows co-localization studies with other proteins of interest. Both cultured cells (IF-cc) and paraffin-embedded tissue sections (IF-p) protocols are available with validated antibodies .

• Flow Cytometry (FACS): Particularly useful for quantifying CMKLR1 expression on immune cells, where this receptor plays important roles in inflammatory regulation .

How can specificity of CMKLR1 antibodies be validated in experimental systems?

Validating CMKLR1 antibody specificity requires a multi-faceted approach:

• Genetic validation: Comparing antibody reactivity in wild-type versus CMKLR1 knockout tissues/cells. The generation of APP/PS1-CMKLR1−/− mice has provided essential negative controls for antibody validation in neurodegeneration research .

• Epitope mapping: Selecting antibodies targeting different regions (N-terminal, C-terminal, or specific amino acid sequences like AA 151-250) of CMKLR1 and confirming concordant results .

• Cross-reactivity assessment: Testing antibody performance across species (human, mouse, rat, pig) and confirming consistent detection patterns. Current commercial antibodies show validated cross-reactivity across multiple mammalian species .

• Blocking peptide controls: Using the specific peptide sequence that the antibody was raised against to pre-absorb the antibody before immunostaining, which should eliminate specific binding signals.

How do post-translational modifications of CMKLR1 affect antibody detection and signaling function?

CMKLR1 undergoes various post-translational modifications that can significantly impact both its detection by antibodies and its signaling capabilities:

• Glycosylation patterns: These vary between tissues and can mask epitopes, particularly in the N-terminal domain. For comprehensive detection, researchers should consider using antibodies targeting multiple regions (AA 8-32, AA 151-250, AA 250-350, and C-terminal domains) .

• Phosphorylation states: The activation of CMKLR1 leads to changes in phosphorylation status that may alter epitope accessibility. This is particularly relevant when studying the receptor's role in tau hyperphosphorylation in Alzheimer's disease models, where phospho-specific antibodies may provide mechanistic insights .

• Dimerization: The structural studies of CMKLR1-Gi signaling complex reveal conformational changes that might obscure certain epitopes upon ligand binding. When studying active versus inactive receptor states, researchers should select antibodies targeting regions less affected by conformational changes .

For comprehensive analysis in signaling studies, combining antibodies that recognize different states of the receptor (active/inactive) provides more complete information than single-epitope approaches.

What are the methodological considerations when investigating CMKLR1's role in Alzheimer's disease pathology?

Investigating CMKLR1's role in Alzheimer's disease requires careful consideration of seemingly contradictory findings where CMKLR1 deficiency increases amyloid β deposits while improving cognitive outcomes :

• Experimental model selection: Different AD models highlight distinct aspects of pathology:

  • APP/PS1 transgenic models focus on amyloid pathology

  • Intracerebroventricular-streptozotocin (ICV-STZ) models represent sporadic AD

  • Tau seeding models specifically examine tau propagation mechanisms

• Temporal assessment: Given CMKLR1's dual effects on amyloid accumulation versus tau pathology, longitudinal studies with time-point specific analyses are essential.

• Regional analysis: CMKLR1 expression varies across brain regions, necessitating region-specific investigations using techniques like immunohistochemistry with paraffin-embedded or frozen sections .

• Functional readouts: Combining biochemical measurements (amyloid load, tau phosphorylation) with behavioral assessments (cognitive testing) provides a more complete picture of CMKLR1's role, as demonstrated in studies showing improved cognitive outcomes despite increased amyloid deposition in CMKLR1-deficient mice .

• Mechanistic dissection: In vitro neuronal cell models can help distinguish direct effects of CMKLR1 on tau seeding from indirect inflammatory mechanisms .

How can researchers optimize CMKLR1 antibody-based detection in dual-ligand binding studies?

When studying CMKLR1's interactions with its two primary ligands (chemerin/RARRES2 and resolvin E1), researchers face unique challenges in antibody-based detection:

• Epitope accessibility changes: The structural basis of CMKLR1 signaling reveals conformational changes upon ligand binding that may affect antibody recognition . Select antibodies targeting epitopes distant from the ligand-binding pocket (such as C-terminal domains) for detection in the presence of ligands.

• Competition experiments protocol optimization:

  • Pre-incubation timing: Allow sufficient time (typically 15-30 minutes) for primary ligand binding before introducing competing ligands

  • Buffer composition: Physiological buffers containing divalent cations (Ca²⁺, Mg²⁺) optimize receptor conformational states

  • Temperature considerations: Conduct binding experiments at physiological temperature (37°C) rather than 4°C to maintain native receptor conformations

• Cross-linking strategies: For capturing transient receptor-ligand complexes, implement chemical cross-linking followed by immunoprecipitation with CMKLR1 antibodies. This approach is particularly valuable when studying the lower-affinity interaction with resolvin E1.

• Co-immunoprecipitation optimization: For pull-down studies examining CMKLR1 in complex with signaling partners, select antibodies targeting receptor regions not involved in protein-protein interactions, particularly avoiding the G-protein coupling interface identified in structural studies .

What methodological approaches can resolve contradictory findings regarding CMKLR1's role in inflammation?

CMKLR1 exhibits both pro-inflammatory and anti-inflammatory properties depending on context, creating apparent contradictions in the literature. These methodological approaches can help clarify its role:

• Cell-type specific analysis: CMKLR1 expression across different immune cells (macrophages, neutrophils, dendritic cells) may mediate different inflammatory outcomes. Flow cytometry with CMKLR1 antibodies combined with cell-type markers provides resolution of cell-specific effects .

• Ligand-specific signaling: Chemerin versus resolvin E1 binding to CMKLR1 may activate distinct signaling cascades. Phospho-specific antibodies targeting downstream effectors can differentiate between these pathways:

  • MAPK1/3 (ERK1/2) phosphorylation

  • NF-kappa-B activation status

  • PI3K pathway engagement

• Temporal dynamics: Acute versus chronic inflammation models show different CMKLR1 roles. Design time-course experiments with multiple sampling points and antibody-based detection methods.

• Genetic models combined with biochemical validation: Using CMKLR1-deficient models supplemented with antibody-based confirmation of pathway activation can help resolve whether observed effects are directly receptor-mediated .